What is the CanAssist Breast test?

CanAssist Breast is a prognostic test that helps predict the risk of breast cancer recurrence and supports oncologists in personalizing treatment plans.

How accurate is the CanAssist Breast test?

CanAssist Breast has been validated on South Asian and Caucasian populations, demonstrating high accuracy in predicting recurrence risk.

Breast Cancer Recurrence Test, CanAssistBreast, India

Q: Who can benefit from the CanAssist Breast test?

It is suitable for patients diagnosed with early-stage, hormone receptor-positive breast cancer to determine their recurrence risk.

Biomakar Insights

Scientific Publication by OncoStem

July, 2018

Development of a Novel Proteomic Risk-Classifier for Prognostication of Patients With Early-Stage Hormone Receptor–Positive Breast Cancer

View

Annals of Oncology

Scientific Publication by OncoStem

September, 2017

Risk of recurrence prediction and optimum treatment planning for early stage breast cancer patients: A cost-effective, accurate and broad based solution for Asia

View

Journal of Molecular Biomarkers & Diagnosis

Scientific Publication by OncoStem

January 2017

Assessment of Ki67 As a Prognostic Marker in Hormone Receptor Positive Breast Cancer: A Retrospective Study on An Indian Cohort

View

South Asian Journal of Cancer

Scientific Publication by Renowned Oncologists Worldwide

31 December, 2021

Purvish Parikh et al: Practical Consensus Recommendations for Optimizing Risk versus Benefit of Chemotherapy in Patients with HR Positive Her2 Negative Early Breast Cancer in India

View

Scientific Publications